$BDTX
Black Diamond Therapeutics Inc

2020 Q1 Form 10-Q Financial Statement

#000170154120000018 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.530M $830.0K
YoY Change 566.27%
% of Gross Profit
Research & Development $7.354M $3.013M
YoY Change 144.08%
% of Gross Profit
Depreciation & Amortization $10.00K $12.00K
YoY Change -16.67%
% of Gross Profit
Operating Expenses $12.88M $3.841M
YoY Change 235.3% 139.31%
Operating Profit -$12.88M -$3.841M
YoY Change 235.3% 139.31%
Interest Expense $740.0K $10.00K
YoY Change 7300.0%
% of Operating Profit
Other Income/Expense, Net $734.0K $13.00K
YoY Change 5546.15%
Pretax Income -$12.15M -$3.830M
YoY Change 217.23%
Income Tax
% Of Pretax Income
Net Earnings -$12.15M -$3.828M
YoY Change 217.27% 140.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$0.51 -$117.3K
COMMON SHARES
Basic Shares Outstanding 23.70M shares
Diluted Shares Outstanding 23.70M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $357.2M
YoY Change
Cash & Equivalents $357.2M $44.72M
Short-Term Investments
Other Short-Term Assets $4.900M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $362.1M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $154.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $79.00K
YoY Change
Total Long-Term Assets $717.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $362.1M
Total Long-Term Assets $717.0K
Total Assets $362.8M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.798M
YoY Change
Accrued Expenses $2.538M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.300M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $200.0K
YoY Change
Total Long-Term Liabilities $200.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.300M
Total Long-Term Liabilities $200.0K
Total Liabilities $7.539M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$63.12M
YoY Change
Common Stock $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $355.3M -$19.28M
YoY Change
Total Liabilities & Shareholders Equity $362.8M
YoY Change

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$12.15M -$3.828M
YoY Change 217.27% 140.45%
Depreciation, Depletion And Amortization $10.00K $12.00K
YoY Change -16.67%
Cash From Operating Activities -$11.32M -$6.878M
YoY Change 64.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $10.00K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $213.8M $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -$11.32M -$6.878M
Cash From Investing Activities $0.00 -$10.00K
Cash From Financing Activities $213.8M $0.00
Net Change In Cash $202.5M -$6.888M
YoY Change -3040.26%
FREE CASH FLOW
Cash From Operating Activities -$11.32M -$6.878M
Capital Expenditures $0.00 $10.00K
Free Cash Flow -$11.32M -$6.888M
YoY Change 64.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001701541
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei Entity File Number
EntityFileNumber
001-38501
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
BLACK DIAMOND THERAPEUTICS, INC.
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Assets
Assets
158295000 USD
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4254660
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
139 Main Street
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2020Q1 dei City Area Code
CityAreaCode
(617)
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
252-0848
CY2020Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001
CY2020Q1 dei Trading Symbol
TradingSymbol
BDTX
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35910705 shares
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
357191000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154666000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4896000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1048000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
362087000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
155714000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000 USD
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
55000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
55000 USD
CY2020Q1 us-gaap Deferred Costs
DeferredCosts
0 USD
CY2019Q4 us-gaap Deferred Costs
DeferredCosts
2303000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
429000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59000 USD
CY2020Q1 us-gaap Assets
Assets
362804000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4863000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3798000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1964000 USD
CY2020Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
964000 USD
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2538000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2899000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7300000 USD
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
239000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
7539000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
4879000 USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
200573000 USD
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35910705 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35910705 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2236672 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2236672 shares
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
418375000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3812000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63115000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50970000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
355265000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-47157000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
362804000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
158295000 USD
CY2020Q1 bdtx Related Party Transaction Research And Development Expenses From Transactions With Related Party
RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
1880000 USD
CY2019Q1 bdtx Related Party Transaction Research And Development Expenses From Transactions With Related Party
RelatedPartyTransactionResearchAndDevelopmentExpensesFromTransactionsWithRelatedParty
1940000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7354000 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3013000 USD
CY2020Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
0 USD
CY2019Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
11000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5525000 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
828000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
12879000 USD
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3841000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12879000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3841000 USD
CY2020Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
744000 USD
CY2019Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
11000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
734000 USD
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.87
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23699255 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2044380 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1877000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
10000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
12000 USD
CY2020Q1 bdtx Rent Expense
RentExpense
47000 USD
CY2019Q1 bdtx Rent Expense
RentExpense
0 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3848000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1195000 USD
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
20000 USD
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
16000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2394000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-54000 USD
CY2020Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
964000 USD
CY2019Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-1707000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-547000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-181000 USD
CY2020Q1 bdtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-51000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11319000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6878000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1275000 USD
CY2020Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
213844000 USD
CY2019Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
213844000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
202525000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6888000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
154721000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51660000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357246000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44772000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
357191000 USD
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44717000 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
55000 USD
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
55000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357246000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44772000 USD
CY2020Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
200573000 USD
CY2019Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 USD
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33668075 shares
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60770000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-15542000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2019Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33668075 shares
CY2019Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60770000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-19279000 USD
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
64839353 shares
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
200573000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-47157000 USD
CY2020Q1 bdtx Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
64839353 shares
CY2020Q1 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
200573000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200573000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
212101000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1877000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
355265000 USD
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.01581
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63115000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50970000 USD
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
CY2019Q4 us-gaap Deferred Costs
DeferredCosts
2303000 USD
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
16000 USD
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
276000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
276000 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
122000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
112000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
154000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
10000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
12000 USD
CY2020Q1 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
473000 USD
CY2019Q4 bdtx Accrued Contract Research Service Fees Current
AccruedContractResearchServiceFeesCurrent
434000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1002000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1182000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
760000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
984000 USD
CY2020Q1 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
107000 USD
CY2019Q4 bdtx Accrued Legal Fees Current
AccruedLegalFeesCurrent
299000 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196000 USD
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2538000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2899000 USD
CY2020Q1 bdtx Shares Authorized
SharesAuthorized
510000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
741347 shares
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1877000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000 USD
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
714000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3082346 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
37475 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.93
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18088000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12145000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3828000 USD
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23699255 shares
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2044380 shares
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
56000 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.87
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3082346 shares
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11428764 shares
CY2020Q1 bdtx Lessee Operating Lease Number Of Contracts
LesseeOperatingLeaseNumberOfContracts
1 contract
CY2019Q1 bdtx Lessee Operating Lease Area
LesseeOperatingLeaseArea
2357 sqft
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
160000 USD
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
12000 USD
CY2020Q1 us-gaap Lease Cost
LeaseCost
228000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
55000 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.086
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
168000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
228000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
77000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
473000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
38000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
435000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
223000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
228000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
77000 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0 USD
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
528000 USD
CY2020Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2020Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
149000 USD
CY2019Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
23000 USD
CY2020Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
964000 USD
CY2019Q4 bdtx Prepaid Expense Related Party Current
PrepaidExpenseRelatedPartyCurrent
916000 USD
CY2020Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1880000 USD
CY2019Q1 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1951000 USD

Files In Submission

Name View Source Status
0001701541-20-000018-index-headers.html Edgar Link pending
0001701541-20-000018-index.html Edgar Link pending
0001701541-20-000018.txt Edgar Link pending
0001701541-20-000018-xbrl.zip Edgar Link pending
bdtx-20200331.htm Edgar Link pending
bdtx-20200331.xsd Edgar Link pending
bdtx-20200331_cal.xml Edgar Link unprocessable
bdtx-20200331_def.xml Edgar Link unprocessable
bdtx-20200331_htm.xml Edgar Link completed
bdtx-20200331_lab.xml Edgar Link unprocessable
bdtx-20200331_pre.xml Edgar Link unprocessable
exhibit311q12020.htm Edgar Link pending
exhibit312q12020.htm Edgar Link pending
exhibit321q12020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending